Investment Notes: Remedy Robotics

Remedy Robotics has unveiled the world’s first remotely operated surgical robot for neurovascular intervention - and demonstrated its breakthrough technology through successful, fully remote, in-human procedures across two Toronto hospitals.

It’s a milestone moment, not just for the company but for modern medicine. For us at Blackbird, it’s also the first time we can share publicly that we’ve been proud investors in Remedy since their Series A in 2020.

Why Remedy?

Stroke is the number one cause of disability and the second leading cause of death worldwide. For large-vessel occlusion (LVO) strokes - among the most devastating kind - the gold standard treatment is a mechanical thrombectomy. But access is vanishingly rare. In the US, more than 90% of hospitals lack the specialists to be able perform it. Globally, fewer than 3% of eligible patients receive treatment in time.

Remedy is tackling this as a talent distribution problem. There are simply too few interventionists, clustered in major metropolitan hospitals, to meet the global need.

Their solution is both breathtaking in ambition and elegant in logic: build a network of remotely-operated surgical robots so that the best doctors in the world can treat patients anywhere, in real time. A patient in Lismore could be operated on by a specialist at Westmead. One in Bangalore by a surgeon in Boston.

Over time, the platform can expand to a full suite of time-critical cardiovascular procedures - aneurysms, brain bleeds, pulmonary embolisms, heart attacks - potentially transforming care for millions of people.

The founders

David Bell (CEO and co-founder) is a cardiothoracic surgeon turned founder, and one of the most compelling storytellers we’ve ever met. He combines deep clinical empathy with the conviction that surgery itself should be reimagined.

Jake Sganga (CTO and co-founder) is a Stanford-trained PhD with world-class expertise in surgical robotics, computer vision, and mechanical engineering. He brings the technical imagination - and the sheer product obsession - to make the vision real.

Together, David and Jake embody the wild hearts we look for: relentless in ambition, precise in execution, and motivated by a mission much bigger than themselves.

From vision to milestone

Since we first invested, the Remedy team has moved at astonishing speed. What began as a second hand X-ray machine in a garage idea has now achieved a world-first: the successful completion of fully remote, human endovascular procedures across two hospitals in Toronto.

These procedures demonstrate not just the feasibility but the safety, precision, and reliability of the Remedy system in real-world conditions. They mark the beginning of a future where access to life-saving intervention is no longer defined by geography.

Why we believe

Remedy represents everything we look for in a generational company:

• A problem of profound global importance — cardiovascular disease kills 19 million people each year.
  
  
• A visionary solution — using robotics and applied AI to remove the talent bottleneck in life-saving procedures.
  
  
• Wild-hearted founders — David and Jake, who combine deep expertise with relentless ambition.

It is no exaggeration to say that Remedy could change the lives of millions who today face death or disability simply because they live too far from a specialist hospital.

We’re proud to be on this journey with them — from the first belief, to today’s milestone, and the generational company we believe Remedy can become.

‍